SKAN Group AG

LSE:0SKN Stock Report

Market Cap: CHF 1.7b

SKAN Group Valuation

Is 0SKN undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 0SKN when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 0SKN (CHF77.9) is trading below our estimate of fair value (CHF86.09)

Significantly Below Fair Value: 0SKN is trading below fair value, but not by a significant amount.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 0SKN?

Key metric: As 0SKN is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 0SKN. This is calculated by dividing 0SKN's market cap by their current earnings.
What is 0SKN's PE Ratio?
PE Ratio53.8x
EarningsCHF 32.24m
Market CapCHF 1.74b

Price to Earnings Ratio vs Peers

How does 0SKN's PE Ratio compare to its peers?

The above table shows the PE ratio for 0SKN vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average46.2x
ERGO Ergomed
46.7x14.2%UK£701.1m
HVO hVIVO
7.4x-29.6%UK£130.0m
C4XD C4X Discovery Holdings
2.9x-88.3%UK£30.3m
GNS Genus
127.9x31.5%UK£1.0b
0SKN SKAN Group
53.8x17.8%CHF 1.7b

Price-To-Earnings vs Peers: 0SKN is expensive based on its Price-To-Earnings Ratio (53.8x) compared to the peer average (46.1x).

Price to Earnings Ratio vs Industry

How does 0SKN's PE Ratio compare vs other companies in the European Life Sciences Industry?

1 CompanyPrice / EarningsEstimated GrowthMarket Cap
0SKN 53.8xIndustry Avg. 39.0xNo. of Companies3PE020406080100+
1 CompanyEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: 0SKN is expensive based on its Price-To-Earnings Ratio (53.8x) compared to the European Life Sciences industry average (39x).

Price to Earnings Ratio vs Fair Ratio

What is 0SKN's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

0SKN PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio53.8x
Fair PE Ratio23.5x

Price-To-Earnings vs Fair Ratio: 0SKN is expensive based on its Price-To-Earnings Ratio (53.8x) compared to the estimated Fair Price-To-Earnings Ratio (23.5x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 0SKN forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentCHF 77.90
CHF 90.67
+16.4%
2.9%CHF 93.00CHF 87.00n/a3
Dec ’25CHF 75.10
CHF 90.00
+19.8%
3.3%CHF 93.00CHF 87.00n/a2
Nov ’25CHF 77.30
CHF 90.00
+16.4%
3.3%CHF 93.00CHF 87.00n/a2
Oct ’25CHF 80.00
CHF 90.00
+12.5%
3.3%CHF 93.00CHF 87.00n/a2
Sep ’25CHF 81.00
CHF 97.50
+20.4%
10.8%CHF 108.00CHF 87.00n/a2
Aug ’25CHF 79.70
CHF 97.50
+22.3%
10.8%CHF 108.00CHF 87.00n/a2
Jul ’25CHF 80.00
CHF 97.50
+21.9%
10.8%CHF 108.00CHF 87.00n/a2
Jun ’25CHF 80.40
CHF 95.67
+19.0%
9.4%CHF 108.00CHF 87.00n/a3
May ’25CHF 82.24
CHF 91.33
+11.1%
15.2%CHF 108.00CHF 74.00n/a3
Apr ’25CHF 85.10
CHF 91.33
+7.3%
15.2%CHF 108.00CHF 74.00n/a3
Mar ’25CHF 82.17
CHF 91.33
+11.2%
15.2%CHF 108.00CHF 74.00n/a3
Feb ’25CHF 75.81
CHF 91.33
+20.5%
15.2%CHF 108.00CHF 74.00n/a3
Jan ’25CHF 81.01
CHF 91.33
+12.7%
15.2%CHF 108.00CHF 74.00CHF 76.203
Dec ’24CHF 78.20
CHF 91.33
+16.8%
15.2%CHF 108.00CHF 74.00CHF 75.103
Nov ’24CHF 69.51
CHF 91.33
+31.4%
15.2%CHF 108.00CHF 74.00CHF 77.303
Oct ’24CHF 77.72
CHF 91.00
+17.1%
18.7%CHF 108.00CHF 74.00CHF 80.002
Sep ’24CHF 79.43
CHF 92.33
+16.3%
15.2%CHF 108.00CHF 74.00CHF 81.003
Aug ’24CHF 79.72
CHF 100.50
+26.1%
5.5%CHF 106.00CHF 95.00CHF 79.702
Jul ’24CHF 77.00
CHF 100.50
+30.5%
5.5%CHF 106.00CHF 95.00CHF 80.002
Jun ’24CHF 79.91
CHF 100.50
+25.8%
5.5%CHF 106.00CHF 95.00CHF 80.402
May ’24CHF 86.19
CHF 94.00
+9.1%
12.8%CHF 106.00CHF 82.00CHF 82.242
Apr ’24CHF 83.33
CHF 94.00
+12.8%
12.8%CHF 106.00CHF 82.00CHF 85.102
Mar ’24CHF 69.27
CHF 86.50
+24.9%
22.5%CHF 106.00CHF 67.00CHF 82.172
Feb ’24CHF 68.83
CHF 86.50
+25.7%
22.5%CHF 106.00CHF 67.00CHF 75.812
Jan ’24CHF 63.42
CHF 86.50
+36.4%
22.5%CHF 106.00CHF 67.00CHF 81.012

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/05 10:47
End of Day Share Price 2025/01/03 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

SKAN Group AG is covered by 6 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Volker BosseBaader Helvea Equity Research
Leonildo DelgadoBaader Helvea Equity Research
Samuel EnglandBerenberg